355 related articles for article (PubMed ID: 27170229)
1. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists.
Rizos A; Sauerbier A; Antonini A; Weintraub D; Martinez-Martin P; Kessel B; Henriksen T; Falup-Pecurariu C; Silverdale M; Durner G; Røkenes Karlsen K; Grilo M; Odin P; Chaudhuri KR;
Eur J Neurol; 2016 Aug; 23(8):1255-61. PubMed ID: 27170229
[TBL] [Abstract][Full Text] [Related]
2. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
[TBL] [Abstract][Full Text] [Related]
3. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.
Antonini A; Chaudhuri KR; Boroojerdi B; Asgharnejad M; Bauer L; Grieger F; Weintraub D
Eur J Neurol; 2016 Oct; 23(10):1556-65. PubMed ID: 27425586
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey.
Rizos A; Sauerbier A; Falup-Pecurariu C; Odin P; Antonini A; Martinez-Martin P; Kessel B; Henriksen T; Silverdale M; Durner G; Ray Chaudhuri K;
J Neural Transm (Vienna); 2020 Jun; 127(6):875-879. PubMed ID: 32372166
[TBL] [Abstract][Full Text] [Related]
5. Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease.
Gungabissoon U; Kirichek O; El Baou C; Galwey N
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):591-598. PubMed ID: 32153056
[TBL] [Abstract][Full Text] [Related]
6. Impulse control disorders in Parkinson's disease: a retrospective analysis of 1824 patients in a 12-year period.
Gunduz A; Çiftçi T; Erbil AC; Senoglu G; Ser MH; Apaydın H
Neurol Sci; 2024 Jan; 45(1):171-175. PubMed ID: 37581771
[TBL] [Abstract][Full Text] [Related]
7. Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.
Contin M; Lopane G; Marini L; Mohamed S; Sambati L; De Massis P; Guarino M; Sermi S; Persichella C; Cortelli P; Calandra-Buonaura G
Neurol Sci; 2023 Feb; 44(2):565-572. PubMed ID: 36350455
[TBL] [Abstract][Full Text] [Related]
8. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
[TBL] [Abstract][Full Text] [Related]
9. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
10. Impulse Control and Related Disorders in Parkinson's Disease.
Weintraub D; Claassen DO
Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
[TBL] [Abstract][Full Text] [Related]
11. Clinical spectrum of impulse control disorders in Parkinson's disease.
Weintraub D; David AS; Evans AH; Grant JE; Stacy M
Mov Disord; 2015 Feb; 30(2):121-7. PubMed ID: 25370355
[TBL] [Abstract][Full Text] [Related]
12. Dopamine and impulse control disorders in Parkinson's disease.
Weintraub D
Ann Neurol; 2008 Dec; 64 Suppl 2(Suppl 2):S93-100. PubMed ID: 19127573
[TBL] [Abstract][Full Text] [Related]
13. What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson's disease? A preliminary pharmacoepidemiologic study.
Jeon N; Bortolato M
PLoS One; 2020; 15(1):e0227128. PubMed ID: 31910240
[TBL] [Abstract][Full Text] [Related]
14. [Impulsive-compulsive behaviours in a German Parkinson's disease outpatient sample].
Rohde K; Riedel O; Lueken U; Rietzel S; Fauser M; Ossig C; Reichmann H; Storch A
Fortschr Neurol Psychiatr; 2013 Sep; 81(9):503-10. PubMed ID: 23986458
[TBL] [Abstract][Full Text] [Related]
15. Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease.
Bellosta Diago E; Lopez Del Val LJ; Santos Lasaosa S; López Garcia E; Viloria Alebesque A
Neurologia; 2017 Oct; 32(8):494-499. PubMed ID: 27087472
[TBL] [Abstract][Full Text] [Related]
16. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions.
Ramirez-Zamora A; Gee L; Boyd J; Biller J
Expert Rev Neurother; 2016; 16(4):389-99. PubMed ID: 26923084
[TBL] [Abstract][Full Text] [Related]
17. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
[TBL] [Abstract][Full Text] [Related]
18. Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
Staubo SC; Fuskevåg OM; Toft M; Lie IH; Alvik KMJ; Jostad P; Tingvoll SH; Lilleng H; Rosqvist K; Størset E; Odin P; Dietrichs E; Dietrichs ES
Eur J Neurol; 2024 Feb; 31(2):e16144. PubMed ID: 37955562
[TBL] [Abstract][Full Text] [Related]
19. Impulse control disorders in Parkinson's disease.
Weintraub D; Potenza MN
Curr Neurol Neurosci Rep; 2006 Jul; 6(4):302-6. PubMed ID: 16822350
[TBL] [Abstract][Full Text] [Related]
20. Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort.
Jesús S; Labrador-Espinosa MA; Adarmes AD; Méndel-Del Barrio C; Martínez-Castrillo JC; Alonso-Cánovas A; Sánchez Alonso P; Novo-Ponte S; Alonso-Losada MG; López Ariztegui N; Segundo Rodríguez JC; Morales MI; Gastón I; Lacruz Bescos F; Clavero Ibarra P; Kulisevsky J; Pagonabarraga J; Pascual-Sedano B; Martínez-Martín P; Santos-García D; Mir P;
Sci Rep; 2020 Oct; 10(1):16893. PubMed ID: 33037247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
